Sutro Biopharma Reports Strong Q1, $10M Astellas Milestone, Cash Runway to Q2 2028
summarizeSummary
Sutro Biopharma reported its first-quarter 2026 financial results, highlighting a strong balance sheet with $202.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026. This cash position, which includes proceeds from recent capital raises, is expected to fund operations into at least the second quarter of 2028, reiterating the runway previously announced in an 8-K on March 23, 2026. The company also announced a $10 million milestone payment received in April 2026 from its collaboration with Astellas, as their first dual-payload iADC entered the clinic and began patient dosing. Additionally, Sutro provided updates on its wholly-owned pipeline, including STRO-004's Phase 1 trial progressing towards initial data in mid-2026, and planned IND submissions for STRO-006 and STRO-227 in 2026. This comprehensive update confirms financial stability and demonstrates significant progress across its clinical and partnered programs, providing positive catalysts for the stock.
At the time of this announcement, STRO was trading at $38.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $636.5M. The 52-week trading range was $6.74 to $41.88. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.